Cipla (CIPLA) Fundamentals 2026 — P/E 29.5x, Revenue Analysis | SniperIQ
Cipla (CIPLA) is a India-listed Healthcare company in Drug Manufacturers - General with a market capitalization of ₹1.14 Lakh Crore, trading at ₹1415.10 on the BSE. This SniperIQ fundamentals page covers Cipla's valuation (P/E 29.5x, P/B 3.3x), profitability (net margin 13.8%), revenue (₹28,163 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Cipla's market cap?
Cipla (CIPLA) has a market capitalization of approximately ₹1.14 Lakh Crore, trading at ₹1415.10 on the BSE. Market cap moves with the live share price.
What is Cipla's P/E ratio?
Cipla's trailing twelve-month P/E ratio is 29.5x, with a price-to-book (P/B) of 3.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Cipla?
Cipla runs a net profit margin of 13.8%, a gross margin of 48.2%, and an operating margin of 16.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Cipla generate?
Cipla reported revenue of ₹28,163 Crore for fiscal year 2026, with net income of ₹3,879 Crore and earnings per share (EPS) of 48.03. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Cipla pay a dividend?
Cipla offers a trailing dividend yield of about 2.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Cipla financially healthy?
Cipla carries a debt-to-equity ratio of 0.02x and a current ratio of 3.44x, with a market beta of -0.05. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Cipla a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Cipla (CIPLA) the key facts are: market cap ₹1.14 Lakh Crore, P/E 29.5x, revenue ₹28,163 Crore, 52-week range 1283-1672.2. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Cipla's full fundamentals live
Get Cipla's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.